A Phase 3 interventional study of Fixed Combination of Fenofibrate/simvastatin 145/20 mg and Simvastatin 20 mg in Dyslipidemia, sponsored by Abbott. Completed at 69 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-11.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing simvastatin in Dyslipidemias — none open to participants now, none under way, none of them phase 3. Simvastatin · Dyslipidemias.
Among the 21 studies testing simvastatin in Dyslipidemias, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2012, is one of 9 in phase 3, and was the 16th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 21 studies testing simvastatin in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 575 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 155 across the 20 interventional studies. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
22 studies in Dyslipidemias by Abbott: none open now, none under way, none of them phase 3. Of 22 finished, 11 (50%) have results posted.
Among the 22 studies in Dyslipidemias by Abbott, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2012, is one of 15 in phase 3, and was the 20th registered.
Abbott’s Dyslipidemias studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing simvastatin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 22 in Dyslipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized study designed to compare the efficacy and safety of two fixed combinations of fenofibrate / simvastatin 145/20 mg and fenofibrate / simvastatin 145/40 mg tablets vs. matching monotherapies in subjects with abnormal fat (lipids) in the blood and at high risk of cardiovascular disease. Fenofibrate is a treatment that lowers fat in blood. It is prescribed in patients with high levels of triglycerides (TG). The drug has been marketed in more than 80 countries since 1975. Simvastatin is also used for the treatment of patients with a high level of cholesterol. These have also been marketed worldwide for more than 20 years. It is important to treat high levels of fats in the blood because it has been shown that even mildly elevated level of lipids in the blood can lead to diseases of the blood vessels. It has been shown in several studies and in clinical practice that the combination of fenofibrate plus simvastatin can lead to improved effects on blood fats, compared to treatment with simvastatin or fenofibrate alone. The main objective of the study is to compare the efficacy of the two fixed-combinations (FC) -fenofibrate/simvastatin 145/20 mg tablet and fenofibrate/simvastatin 145/40 mg tablet in reducing TG and increasing high density lipoprotein cholesterol (HDL-C) versus simvastatin 20 mg or 40 mg, and in reducing low density lipoprotein cholesterol (LDL-C) versus fenofibrate 145 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
With mixed dyslipidemia with fasting lipid results of a blood sample taken at inclusion and after at least 3 months of any statin monotherapy (excluding simvastatin 80 mg, atorvastatin 40 mg and 80 mg, rosuvastatin 20 mg and 40 mg):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fixed Combination of Fenofibrate/simvastatin 145/20 mg
Drug: Simvastatin 20 mg
Drug: Fenofibrate 145 mg
Drug: Fixed Combination of Fenofibrate/simvastatin 145/40 mg
Drug: Simvastatin 40 mg
Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
Fenofibrate, tablet, 145 mg, once daily, 12 weeks
Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
Percentage of Change of TG (Triglyceride)
Collection and measurement of blood samples.
Time frame: from baseline to 12 weeks of treatment
Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)
Collection and measurement of blood samples.
Time frame: from baseline to 12 weeks of treatment
Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)
Collection and measurement of blood samples.
Time frame: from baseline to 12 weeks of treatment
Percentage of Non-HDL (High Density Lipoprotein)-C From Baseline
Collection and measurement of blood samples
Time frame: 12 weeks
Percentage of TC (Triglyceride) From Baseline
Collection and measurement of blood samples
Time frame: 12 weeks
Percentage of Apolipoprotein AI From Baseline
Collection and measurement of blood samples
Time frame: 12 weeks
Percentage of Apolipoprotein B From Baseline
Collection and measurement of blood samples
Time frame: 12 weeks
Percentage of High-sensitivity C-reactive Protein (hsCRP) From Baseline
Collection and measurement of blood samples
Time frame: 12 weeks
Percentage of Subjects Meeting Target Levels of Lipids (According to Very High or High Risk)
Collection and measurement of blood samples
Time frame: 12 weeks
Adverse Events
Collection and measurement of blood samples
Time frame: 12 weeks
Creatine Kinase (CK)
Collection and measurement of blood samples
Time frame: 12 weeks
Alanine Aminotransferase (ALT)
Collection and measurement of blood samples
Time frame: 12 weeks
Plasma Creatinine
Collection and measurement of blood samples
Time frame: 12 weeks
Total Bilirubin
Collection and measurement of blood samples
Time frame: 12 weeks
Cystatin C
Collection and measurement of blood samples
Time frame: 12 weeks
| Milestone | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg |
|---|---|---|---|---|---|
| Started | 114 | 117 | 115 | 116 | 113 |
| Full analysis subject sample | 109 | 114 | 110 | 112 | 111 |
| Safety subject sample | 111 | 117 | 113 | 115 | 112 |
| Completed | 104 | 108 | 106 | 108 | 102 |
| Not completed | 10 | 9 | 9 | 8 | 11 |
| Withdrew: Adverse event | 5 | 6 | 3 | 4 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 5 | 4 | 3 |
| Withdrew: Administrative | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 1 |
Collection and measurement of blood samples.
| percentage of change | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg |
|---|---|---|---|---|---|
| Percentage of Change of TG (Triglyceride) | -30.6 ± 25.8 | 10.7 ± 48.8 | -27.3 ± 35.9 | -2.9 ± 34.3 | -21.6 ± 34.2 |
Collection and measurement of blood samples.
| percentage of change | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg |
|---|---|---|---|---|---|
| Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol) | 9.0 ± 16.8 | 0.3 ± 12.1 | 8.8 ± 16.5 | 2.2 ± 12.5 | 7.6 ± 15.7 |
Collection and measurement of blood samples.
| percentage of change | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg |
|---|---|---|---|---|---|
| Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol) | 1.9 ± 25.4 | -2.0 ± 24.8 | -6.1 ± 26.2 | -8.1 ± 25.8 | 30.3 ± 35.6 |
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Collection and measurement of blood samples
Results for this outcome have not been posted.
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fenofibrate/Simvastatin 145/20 mg | — | 3/111 (2.7%) | 8/111 (7.2%) |
| Simvastatin 20 mg | — | 3/117 (2.6%) | 7/117 (6%) |
| Fenofibrate/Simvastatin 145/40 mg | — | 3/113 (2.7%) | 4/113 (3.5%) |
| Simvastatin 40 mg | — | 1/115 (0.9%) | 9/115 (7.8%) |
| Fenofibrate 145 mg | — | 3/112 (2.7%) | 15/112 (13.4%) |
| Event | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg |
|---|---|---|---|---|---|
| ACUTE CORONARY SYNDROMECardiac disorders | 1/111 | 0/117 | 0/113 | 0/115 | 0/112 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 1/111 | 0/117 | 0/113 | 0/115 | 0/112 |
| HAEMATURIARenal and urinary disorders | 1/111 | 0/117 | 0/113 | 0/115 | 0/112 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/111 | 0/117 | 0/113 | 0/115 | 1/112 |
| DIABETES MELLITUS INADEQUATE CONTROLMetabolism and nutrition disorders | 0/111 | 0/117 | 0/113 | 0/115 | 1/112 |
| BURSITISMusculoskeletal and connective tissue disorders | 0/111 | 0/117 | 0/113 | 0/115 | 1/112 |
| ANGINA PECTORISCardiac disorders | 0/111 | 0/117 | 1/113 | 0/115 | 0/112 |
| VESTIBULAR DISORDEREar and labyrinth disorders | 0/111 | 0/117 | 1/113 | 0/115 | 0/112 |
| INTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/111 | 0/117 | 1/113 | 0/115 | 0/112 |
| UMBILICAL HERNIA, OBSTRUCTIVEGastrointestinal disorders | 0/111 | 0/117 | 1/113 | 0/115 | 0/112 |
| Event | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg |
|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 1/111 | 2/117 | 2/113 | 0/115 | 5/112 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 4/111 | 0/117 | 1/113 | 1/115 | 1/112 |
| GASTROENTERITISInfections and infestations | 1/111 | 2/117 | 0/113 | 0/115 | 4/112 |
| DYSPEPSIAGastrointestinal disorders | 1/111 | 0/117 | 0/113 | 4/115 | 1/112 |
| NASOPHARYNGITISInfections and infestations | 1/111 | 0/117 | 1/113 | 3/115 | 3/112 |
| COUGHRespiratory, thoracic and mediastinal disorders | 0/111 | 3/117 | 0/113 | 1/115 | 1/112 |
Full analysis subject sample
| Age, Continuous(years) | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 59.6 ± 10 | 60.5 ± 9.3 | 60.4 ± 8.1 | 59.3 ± 9.1 | 60.4 ± 9.0 | 60.0 ± 9.1 |
| Sex: Female, Male(Participants) | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg | Total |
|---|---|---|---|---|---|---|
| Female | 38 | 40 | 43 | 39 | 38 | 198 |
| Male | 71 | 74 | 67 | 73 | 73 | 358 |
| Region of Enrollment(participants) | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg | Total |
|---|---|---|---|---|---|---|
| Czech Republic | 22 | 22 | 22 | 23 | 21 | 110 |
| Mexico | 7 | 9 | 8 | 7 | 8 | 39 |
| Argentina | 19 | 22 | 19 | 20 | 21 | 101 |
| Poland | 7 | 9 | 8 | 10 | 7 | 41 |
| Romania | 6 | 6 | 6 | 5 | 4 | 27 |
| Russian Federation | 18 | 17 | 16 | 16 | 17 | 84 |
| Germany | 30 | 29 | 31 | 31 | 33 | 154 |
| Triglycerides (mmol/L)(mmol/L) | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 2.8 ± 1.1 | 2.5 ± 1.0 | 2.7 ± 1.4 | 2.7 ± 1.0 | 2.9 ± 1.3 | 2.7 ± 1.1 |
| LDL Cholesterol (mmol/L)(mmol/L) | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 2.6 ± 0.5 | 2.6 ± 0.4 | 2.6 ± 0.4 | 2.7 ± 0.4 | 2.7 ± 0.5 | 2.7 ± 0.5 |
| HDL Cholesterol (mmol/L)(mmol/L) | Fenofibrate/Simvastatin 145/20 mg | Simvastatin 20 mg | Fenofibrate/Simvastatin 145/40 mg | Simvastatin 40 mg | Fenofibrate 145 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 |
The record gives a start of Jun 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simvastatin